← 홈

방광·요로상피

85개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-14 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 85개
ADCSHOTFDACuratedFDABiologicRemeGenMMAEApproved

disitamab vedotin (Disitamab Vedotin, RC48)

HER2+ urothelial, gastric, breast · HER2

#HER2#ADC#Approved#FDA승인#바이오모아추천+5
효능 ORR 50%임상시험 146상태 ACTIVE
ADCSFDAFDABiologicAstellasvedotin plus pembrolizumab …Approved

enfortumab vedotin (Padcev)

Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis and Ureter Urothelial Carcinoma · Renal Pelvis and Ureter Urothelial Carci

#RenalPelvisandUreterUrothelialCa#ADC#Approved#FDA승인#인기+5
효능 ORR 44%임상시험 76상태 RECRUITING
CGTSHOTFDACuratedFDABiologicFerring PharmaceuticalsHuman interferon alfa-2bApproved

nadofaragene firadenovec (Adstiladrin, rAd-IFNα/Syn3, nadofaragene firadenovec-vncg)

High-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) · IFNα2b (adenoviral)

#IFN2badenoviral#CGT#Approved#FDA승인#바이오모아추천+5
효능 ORR 55%임상시험 10상태 APPROVED
AntibodyAHotAstraZenecaderuxtecan 3Phase 3

Tremelimumab (Tremelimumab)

Hepatocellular Carcinoma · Muscle Invasive Bladder Cancer

#MuscleInvasiveBladderCancer#Antibody#Phase3#인기#항체+5
효능 ORR 84.6%임상시험 181상태 RECRUITING
ADCCHotBiologicGileadderuxtecan, sacituzumab gov…Phase 2

SG (Sacituzumab Govitecan, Sacituzumab Govitecan (SG))

Urothelial Carcinoma; Muscle-invasive Bladder Cancer · Urothelial Cancer

#UrothelialCancer#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 44%임상시험 121상태 RECRUITING
ADCBHotBiologicAstellasvedotin plus pembrolizumab …Phase 3

EV (enfortumab vedotin, enfortumab vedotin (EV))

Urothelial Carcinoma (UC); Peripheral Nerve Disease · Carcinoma, Transitional Cell

#CarcinomaTransitionalCell#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 44%임상시험 117상태 RECRUITING
ADCBHotBiologicPharmacyclics LLC.Phase 3

Ibrutinib (Ibrutinib)

Metastatic Renal Cell Carcinoma; Advanced Urothelial Carcinoma · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 93.9%임상시험 105상태 ACTIVE
ADCBiologicAstellasvedotin (ARON-2EV study)Phase 2

EV (Enfortumab vedotin-ejfv, Enfortumab vedotin-ejfv (EV))

Urothelial Cancer; Metastatic Urothelial Carcinoma · Urothelial Cancer

#UrothelialCancer#ADC#Phase2#인기#항체약물접합체+5
임상시험 67상태 RECRUITING
ADCBiologicAstraZenecaVedotin in a Hemodialysis P…Phase 3

Gemcitabine/Carboplatin (Gemcitabine/Carboplatin)

Non-Small-Cell Lung Carcinoma NSCLC · Muscle Invasive Bladder Urothelial Carci

#MuscleInvasiveBladderUrothelialC#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 69.6%임상시험 67상태 ACTIVE
AntibodyGenentech, Inc.Phase 3

Tiragolumab (Tiragolumab)

Multiple Myeloma; Non-Hodgkin Lymphoma · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase3#인기#항체+5
효능 ORR 77.3%임상시험 64상태 ACTIVE
ADCBiologicFondazione Italiana Linfomi - E…vedotin, nivolumab, doxorub…Phase 3

Vinblastine Sulfate (Vinblastine Sulfate)

Renal Pelvis and Ureter Urothelial Carcinoma · Lugano Classification Limited Stage Hodg

#LuganoClassificationLimitedStage#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 96%임상시험 63상태 RECRUITING
ADCBiologicMedical Enterprises Europe B.V.Phase 3

Mitomycin C (Mitomycin C)

Locally Advanced Cancer in the Anal Region · Urothelial Cancer

#UrothelialCancer#ADC#Phase3#인기#항체약물접합체+4
임상시험 62상태 RECRUITING
AntibodyRochegovitecan in patients with …Phase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody)

Bladder Cancer · Bladder Cancer

#BladderCancer#Antibody#Phase3#인기#항체+4
효능 ORR 75%임상시험 61상태 ACTIVE
ADCBiologicMerck Sharp & Dohme LLCPhase 1

Gemcitabine/Cisplatin II (Gemcitabine/Cisplatin II)

Muscle Invasive Bladder Urothelial Carcinoma · Muscle Invasive Bladder Urothelial Carci

#MuscleInvasiveBladderUrothelialC#ADC#Phase1#인기#항체약물접합체+2
효능 ORR 72%임상시험 60상태 ACTIVE
ADCBiologicMonika Joshi, MDviaPhase 3

Eribulin mesylate (Eribulin mesylate)

Metastatic Urothelial Cell Cancer · Breast Cancer

#BreastCancer#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 71.2%임상시험 59상태 RECRUITING
CGTBiologicSPP Pharmaclon Ltd.Phase 2

Recombinant Interferon Alfa (Recombinant Interferon Alfa)

Colorectal Cancer; Kidney Cancer · Bladder Cancer

#BladderCancer#CGT#Phase2#인기#세포유전치료+5
효능 ORR 32.4%임상시험 59상태 ACTIVE
ADCBiologicFavrillederuxtecan for metastatic b…Phase 2

Antibody-Drug Conjugate Therapy (Antibody-Drug Conjugate Therapy)

Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis and Ureter Urothelial Carcinoma · FRα

#FR#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 86%임상시험 58상태 RECRUITING
ADCBiologicRemeGen Co., Ltd.sPhase 2

disitamab vedotin (Disitamab Vedotin, RC48)

Non-Muscle Invasive Bladder Cancer; HER2 · Gastric Cancer/Gastroesophageal Junction

#GastricCancerGastroesophagealJun#ADC#Phase2#인기#항체약물접합체+5
임상시험 56상태 RECRUITING
ADCBiologicClovis Oncology, Inc.vedotin after avelumabPhase 1

Gemcitabine/Cisplatin I (Gemcitabine/Cisplatin I)

Muscle Invasive Bladder Urothelial Carcinoma · Muscle Invasive Bladder Urothelial Carci

#MuscleInvasiveBladderUrothelialC#ADC#Phase1#인기#항체약물접합체+4
효능 ORR 45.2%임상시험 55상태 ACTIVE
ADCBiologicVadim S Koshkinvedotin (BT8009) and dual-A…Phase 1

N803 (Nogapendekin Alfa Inbakicept, Nogapendekin Alfa Inbakicept (N803))

Metastatic Urothelial Carcinoma; Urothelial Carcinoma · Metastatic Urothelial Carcinoma

#MetastaticUrothelialCarcinoma#ADC#Phase1#인기#항체약물접합체+5
효능 ORR 80%임상시험 53상태 DISCONTINUED

1 / 5 페이지

← 이전다음 →